Performance of Alpha Fetoprotein in Combination with Alpha-1-acid Glycoprotein for Diagnosis of Hepatocellular Carcinoma Among Liver Cirrhosis Patients
ABSTRACT: to evaluate the use
of alpha-1-acid glycoprotein (AAG) for diagnosing hepatocellular carcinoma (HCC),
and to combine with alpha fetoprotein (AFP) as part of routine examination in
liver cirrhosis patients. Methods: this is a diagnostic study using
cross-sectional design. A hundred and six patients were included in this study.
Baseline data such as age, gender, AFP, AAG, peripheral blood count, AST and
ALT were consecutively collected from liver cirrhosis patients with or without
HCC. Serum AAG were measured quantitatively using immunoturboditimetric assay
and AFP with enzyme immune assay (EIA). Statistical analysis were done using SPSS
13.0. Data comparisons between group were done using Mann-Whitney test.
Diagnostic performance for each marker alone was compared to the surrogate use
of both markers (combined parallel approach) in HCC cases. Results: receiver
operating characteristic (ROC) analysis showed that area under the curve for
AFP-AAG combination was 88.1% and higher than AFP only (86.2%) or AAG only
(76.5%) with sensitivity of 83%, 73% and 44%, respectively, at specifcity of
>80%. Conclusion: our study showed that combination of AFP and AAG is
superior than either marker alone in diagnosing HCC in liver cirrhosis
patients. Combination of AFP and AAG may be used to prompt early diagnosis
screening of HCC.
Author: Rino A. Gani, Maulana
Suryamin, Irsan Hasan, C. Rinaldi A. Lesmana, Andri Sanityoso
Journal Code: jpkedokterangg150243
